Cargando…

Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP‐164 study)

Patients with transplant‐ineligible relapsed and refractory multiple myeloma (RRMM) have a short life expectancy, especially when they have failed both the proteasome inhibitor and immunomodulator therapies. This study aimed to assess the efficacy and safety of pomalidomide, cyclophosphamide, and de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Ho Sup, Kim, Kihyun, Kim, Seok Jin, Lee, Je‐Jung, Kim, Inho, Kim, Jin Seok, Eom, Hyeon‐Seok, Yoon, Dok Hyun, Suh, Cheolwon, Shin, Ho‐Jin, Mun, Yeung‐Chul, Kim, Min Kyoung, Lim, Sung‐Nam, Choi, Chul Won, Kang, Hye Jin, Yoon, Sung‐Soo, Min, Chang‐Ki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983889/ https://www.ncbi.nlm.nih.gov/pubmed/31919872 http://dx.doi.org/10.1002/ajh.25726

Ejemplares similares

Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study)
por: Song, Ga-Young, et al.
Publicado: (2022)

Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study
por: Kwon, Jihyun, et al.
Publicado: (2016)

Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party
por: Kim, Seok Jin, et al.
Publicado: (2016)

Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study
por: Jung, Jongheon, et al.
Publicado: (2023)

Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation
por: Lee, Ho Sup, et al.
Publicado: (2013)

Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma
por: Kim, Sung Min, et al.
Publicado: (2014)

Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2019)

The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
por: Kim, Cheolsu, et al.
Publicado: (2015)

Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea
por: Kim, Hyo Jung, et al.
Publicado: (2015)

Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
por: Byun, Ja Min, et al.
Publicado: (2022)

Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party
por: Jung, Sung-Hoon, et al.
Publicado: (2022)

Pomalidomide for the Treatment of Multiple Myeloma
por: Clark, Stephen M., et al.
Publicado: (2014)

Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents
por: Lee, Sung-Eun, et al.
Publicado: (2018)

Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)
por: Song, Ga-Young, et al.
Publicado: (2023)

Distinct Clinical Outcomes between Paramedullary and Extramedullary Lesions in Newly Diagnosed Multiple Myeloma
por: Batsukh, Khishigjargal, et al.
Publicado: (2017)

Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma
por: Kim, Hyun-Young, et al.
Publicado: (2022)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma
por: Song, Ga-Young, et al.
Publicado: (2020)

Exosomal miR-1305 in the oncogenic activity of hypoxic multiple myeloma cells: a biomarker for predicting prognosis
por: Lee, Ji Young, et al.
Publicado: (2021)

Pomalidomide-Induced Pulmonary Toxicity in Multiple Myeloma
por: Modi, Dipenkumar, et al.
Publicado: (2015)

Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen
por: Jung, Sung-Hoon, et al.
Publicado: (2016)

P976: REAL-WORLD OUTCOMES OF PATIENTS WITH PENTA-EXPOSED MULTIPLE MYELOMA WHO WERE TREATED WITH SELINEXOR AND DEXAMETHASONE: KOREAN MULTICENTER RETROSPECTIVE ANALYSIS
por: Ho Yi, Jun, et al.
Publicado: (2023)

Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study
por: Eom, Ki-Seong, et al.
Publicado: (2014)

Bone Marrow Plasma Cell Assessment before Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
por: Lee, Sung-Eun, et al.
Publicado: (2014)

Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient
por: Kang, Wonseok, et al.
Publicado: (2010)

Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma
por: Lee, Yoo Jin, et al.
Publicado: (2019)

Relationship between bortezomib-containing regimens and the incidence of tuberculosis in patients with myeloma
por: Kim, Kihyun, et al.
Publicado: (2013)

Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications
por: Shin, Junghoon, et al.
Publicado: (2017)

Cerebral Infarction in IgG Multiple Myeloma with Hyperviscosity
por: Park, Man-Seok, et al.
Publicado: (2005)

Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation
por: Lee, Sung-Eun, et al.
Publicado: (2019)

Prognostic Significance of Absolute Lymphocyte Count/Absolute Monocyte Count Ratio at Diagnosis in Patients with Multiple Myeloma
por: Shin, Su-Jin, et al.
Publicado: (2013)

New drugs in multiple myeloma – role of carfilzomib and pomalidomide
por: Jurczyszyn, Artur, et al.
Publicado: (2014)

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
por: Chanan-Khan, A A, et al.
Publicado: (2013)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker
por: Ryu, Daeun, et al.
Publicado: (2016)

Circulating CD3(+)CD4(+)CD161(+) Cells Are Associated with Early Complications after Autologous Stem Cell Transplantation in Multiple Myeloma
por: Lee, Sung-Eun, et al.
Publicado: (2018)

P800: CHARACTERIZATION OF REGULATORY T CELLS IN PATIENTS WITH MULTIPLE MYELOMA
por: Kim, Sojeong, et al.
Publicado: (2023)

The impact of novel therapeutic agents before and after frontline autologous stem cell transplantation in patients with multiple myeloma
por: Min, Chang-Ki, et al.
Publicado: (2013)

Daratumumab monotherapy in relapsed and refractory multiple myeloma patients with severely compromised forced expiratory volume in one second
por: Kim, Jin-Hyo, et al.
Publicado: (2022)

Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis
por: Kim, Seok Jin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_um260bkp8cnvcmkukfcl9sbsb5